The University of Chicago Header Logo

Connection

Co-Authors

This is a "connection" page, showing publications co-authored by Anjana Pillai and Chih-Yi Liao.
Connection Strength

0.863
  1. Targeted therapies in hepatocellular carcinoma: past, present, and future. Front Oncol. 2024; 14:1432423.
    View in: PubMed
    Score: 0.246
  2. Perspective: Advances in liver transplantation for hepatocellular carcinoma - A prototype for transplant oncology. Hepatobiliary Pancreat Dis Int. 2023 02; 22(1):4-6.
    View in: PubMed
    Score: 0.215
  3. Survival Outcomes of Radiofrequency Ablation for Intrahepatic Cholangiocarcinoma from the SEER Database: Comparison with Radiotherapy and Resection. J Vasc Interv Radiol. 2024 Nov 02.
    View in: PubMed
    Score: 0.062
  4. Modified Radiation Lobectomy Strategy of Radioembolization for Right-Sided Unresectable Primary Liver Tumors. J Vasc Interv Radiol. 2024 Jul; 35(7):989-997.e2.
    View in: PubMed
    Score: 0.060
  5. Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma. Eur Radiol. 2024 Apr; 34(4):2374-2383.
    View in: PubMed
    Score: 0.058
  6. Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility. J Interv Med. 2023 Nov; 6(4):187-193.
    View in: PubMed
    Score: 0.058
  7. Segmental Yttrium-90 Radioembolization Using Glass Microspheres Greater than 400 Gray for the Treatment of Intrahepatic Cholangiocarcinoma: A Preliminary Experience. J Vasc Interv Radiol. 2023 11; 34(11):1970-1976.e1.
    View in: PubMed
    Score: 0.057
  8. Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol. 2023 04; 34(4):702-709.
    View in: PubMed
    Score: 0.055
  9. Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):202-213.
    View in: PubMed
    Score: 0.054
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.